Conventional wisdom dictates that nonsteroidal anti-inflammatory drugs constitute the best first-line pharmacologic approach to arthritis pain. They work rapidly and provide substantive relief.
New research on pre-emptive nutrition for pro-inflammatory states has revealed startling discoveries on ways through which the body fights pain and inflammation on its own, given the proper circumstances. Insights into the mechanisms of action of omega-3 fatty acids are revolutionizing our approach to the multimodal management of arthritis pain.
Acute inflammation, a defensive response mounted by the host, serves to rid afflicted tissues of the causes and consequences of injury. Chronic inflammation, however, keeps the body locked in a state of perpetuating pain and biochemical unrest.
The omega-3 polyunsatruated fatty acids (PUFA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) facilitate the return of a homeostatic tissue environment.
The mechanisms underlying these changes is catapulting the field of nutritional pharmacology and nutrigenomics to the forefront by providing nutritional approaches to help thwart the inflammatory march toward cancer, Alzheimer’s disease, colitis and periodontal and heart disease.
When healthy individuals suffer trauma, inflammation ensues, but usually eventually disappears. Until recently, how redness, pain, heat and swelling leave the site of injury received little scientific scrutiny; most assumed that once initiators of inflammation left, the body passively recovered.
However, researchers at Harvard Medical School have unearthed novel biochemical pathways and families of endogenous mediators derived from omega-3 polyunsaturated fatty acids that not only prevent but help resolve inflammation.1 They named these mediator families “resolvins” (Rvs) and “protectins” (PDs), to connote their respective roles in controlling the acute inflammatory response and in effecting its resolution.
EPA and DHA, most richly available in fish oil preparations, serve as precursors to resolvins and protectins, which have now joined the first family of mediators, lipoxins (LX) that were previously found to have anti-inflammatory and proresolving activities.
Possibly the most amazing aspect of the resolution angle occurs when polymorphonuclear neutrophils (PMNs) orchestrate the switch from a pro-inflammatory to an inflammation-resolving state.
Instigated by microbes, trauma or cytokines, PMNs incite inflammation by forming the arachidonic acid-derived eicosanoids, prostaglandins and leukotrienes. They accomplish this through enzymatic means, driven by cyclooxygenase (COX) and lipoxygenase (LOX) pathways.
Although NSAIDs and omega-3 fatty acids both reduce the amount of pain inflammation in the body, they do so through markedly different processes.
Although prostaglandins cause much of the pain and edema that clinicians reflexively squelch with NSAIDs, the prostaglandins PGE2 and PGD2 play a dual role by signaling an end to the inflammatory process. Selective COX-2 inhibitors block the production of both PGE2 and PGD2, disrupt the mediator-switching process and may delay the onset of resolution.
When PMNs enter an exudate and make contact with certain tissue constituents and leukocytes nearby, transcellular biosynthesis takes place.
Based on their local environment and biochemical interactions, PMNs have the capacity to switch their phenotype and change their profile of lipid mediator production from leukotrienes to lipoxins. This switch stops more PMNs from entering the exudate and promotes the recruitment of nonphlogistic monocytes. Tissue macrophages engulf and phagocytize the apoptotic PMNs, clearing them from the formerly inflammatory environment and allowing resolution to occur.
Depending on substrate availability, mediator switching can also change from eicosanoids to resolvins and protectins. This is where omega-3 fatty acids enter the scene; when EPA and DHA appear in inflammatory exudates, enzymatic mechanisms lead to the production of LXs, Rvs and PDs.
This shortens the time course of neutrophil infiltration and prompts clearance of apoptotic PMNs. Chemokine deposits clear from the inflammatory site, promoting instead the release of anti-inflammatory cytokines and reparative compounds such as transforming growth factor-1.
But the benefits of omega-3 PUFAs in treating pain go beyond resolving inflammation. Chronic pain and negative mood states display tight linkages.2 Emerging evidence shows that deficiencies in omega-3 fatty-acid intake and increased omega-6 availability in the diet appear to be correlated in humans with disturbances in brain function, and may be associated with increased risk of depression, homicide and suicide.3,4,5
Putative mechanisms explaining the impact of omega-3 fatty acids on psychiatric disorders relate to enhanced serotonergic neurotransmission, changes in dopamine function and other neurotransmitters, and modulation of vagal activity, prevention of neuronal apoptosis, regulated gene expression, competition of EPA with arachidonic acid for enzymatic activities and resultant anti-inflammation, and more.
Another pathway by which omega-3 PUFAs may reduce pain is by interacting directly with an ion channel found in nociceptive neurons and the brain. This capsaicin channel, known also as TRPV1 (for transient receptor potential vanilloid subtype 1), participates in inflammatory pain signaling and may modulate behavior. Although the differential effects of DHA and EPA on TRPV1 are only now coming to light, future work may reveal ways to optimally select for the desired effects through omega 3 supplementation.
Thus, although NSAIDs and omega-3 fatty acids both reduce pain inflammation in the body, they do so through markedly different processes.